A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Phase: PHASE3
Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Sponsor: Kala Pharmaceuticals, Inc.

NCT02819284 
Study ID:  
KPI-121-C-007 (STRIDE 2)  
 
Study Title:  
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% 
Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease 
 
Date:  
06 Jul 2017